Publications by authors named "S Glaser"

Introduction: The World Health Organization global standard for representing drug data is the Anatomical Therapeutic Chemical (ATC) classification. However, it does not represent ingredients and other drug properties required by clinical decision support systems. A mapping to a terminology system that contains this information, like RxNorm, may help fill this gap.

View Article and Find Full Text PDF

Illumina-based BeadChip arrays have revolutionized genome-wide DNA methylation profiling, pushing it into diagnostics. However, comprehensive quality assessment remains challenging within a wide range of available tissue materials and sample preparation methods. This study tackles two critical issues: differentiating between biological effects and technical artefacts in suboptimal quality samples and the impact of the first sample on the Illumina-like normalization algorithm.

View Article and Find Full Text PDF
Article Synopsis
  • Exploiting TRAILR2 activation could improve cancer treatments, but past therapies faced issues like low effectiveness and liver damage.
  • The new TR2/CDH3 BAB antibody targets both CDH3 and TRAILR2, enhancing apoptosis specifically in tumor cells expressing CDH3, showcasing effectiveness in various cancers and CRISPR-engineered models.
  • In pancreatic cancer, where current treatments are lacking, TR2/CDH3 BAB shows promise, especially when used with other chemotherapy drugs, indicating potential for effective cancer therapy with a good safety profile.
View Article and Find Full Text PDF

We report on a 32-year-old woman with multiple, progressive cavitary lung lesions. Lung cavities may occur in the context of various diseases and, thus, represent a huge diagnostic challenge. The spectrum of diseases comprises infections, systemic autoimmune rheumatic diseases, and malignancies.

View Article and Find Full Text PDF

The 8th edition of the American Joint Committee on Cancer integrates histology and biomarker status with anatomic extent in breast cancer (BC) pathologic prognostic staging (PPS). However, PPS IB includes anatomic locally advanced hormone-receptor-positive/HER2-negative (LA-HR+/HER2-) and early-stage triple-negative BC (ES-TNBC). Previous research shows that increased nodal involvement is a critical predictor of worse prognosis, raising questions about whether biological subtype or anatomic stage has a greater influence on outcomes in these discordant cases.

View Article and Find Full Text PDF